Novascular Age-related Macular Degeneration (Wet AMD)

Chengdu Kanghong “Panda2”  (Currently Enrolling)

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration.

Geographic Atrophy (Dry AMD)

Apellis “DERBY” (Enrollment Coming Soon)

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with

Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)


Non-proliferative Diabetic Retinopathy
Regeneron PANORAMA (Enrollment No Longer Open)
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Phase 3 Study. This study will assess the efficacy of intravitreal aflibercept (Eylea) in participants with moderately severe to severe nonproliferative diabetic retinopathy.

Retinal Vein Occlusion
Clearside " Clearside " SAPPHIRE" (Closed)
Study of the safety and efficacy of Suprachoroidal CLS-TA in conjunction with intravitreal aflibercept (Eylea) in the treatment of retinal vein occlusion.
Phase 3 Study. This study will evaluate the combination of Suprachoroidal CLS-TA and Eylea in improving best corrected visual acuity in patients with retinal vein occlusion.

Age-Related Macular Degeneration Research
Roche “ Roche “ AVENUE” (Closed) (Closed)
A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).
Phase 2 Study. This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of RG7716 in participants with subfoveal CNV secondary to AMD.

Diabetic Macular Edema (DME)

Clearside “TYBEE” (Closed)

Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA with Intravitreal Aflibercept versus Aflibercept alone in Subjects with Diabetic Macular Edema.

Coming Soon:

We have additional trials coming up for DME, Wet AMD, and other indications. Feel free to call our Research Department anytime at (541) 770-2020 for a status update on our current trials.